Research says idiopathic thrombocytopenic purpura may be related to AstraZeneca vaccine in rare cases
Visit: Alibaba Cloud 6.18 Main Venue | Tmall 6.18 Super Red Packet Main Venue Jingdong 6.18 “Jingxiang Red Packet” Maximum denomination of 18618 yuan
A low number of platelets (blood cells that help prevent blood loss when blood vessels are damaged) may cause no symptoms, but This may result in an increased risk of bleeding or, in some cases, blood clotting.
Researchers said that the increase in the risk of ITP after vaccination is still less than the risk of ITP due to COVID-19, so the promotion of vaccine programs should not be blocked. Researchers did not find the same risk in Pfizer-BioNTech’s vaccine. Other vaccines were not included in the study.
Experts suggest that Oxford-AstraZeneca vaccine vaccinators should be made aware that the risk of ITP is slightly increased, but they also emphasize that the risk of these diseases of COVID-19 may be much higher.
The British Medicines and Health Products Administration (MHRA). It was previously reported that after vaccination with Oxford-AstraZeneca vaccine, the platelet count was low and accompanied by thrombosis, which is estimated to occur in every million people 13 cases. Experts say that the specific findings about ITP in the new study are likely to be a manifestation of this general situation. MHRA is actively monitoring this situation.
This study surveyed 5.4 million people in Scotland, 2.5 million of whom received their first dose of vaccine. This is the first analysis of ITP, coagulation and bleeding events after vaccination in Scotland.
Researchers were unable to determine the link between other forms of coagulation, including a rare form called cerebral venous sinus thrombosis or CVST, because the number of vaccinated cases included in the study was very small. Those who are most at risk due to ITP are often elderly people – with a median age of 69 years – and have at least one underlying chronic health problem, such as coronary heart disease, diabetes, or chronic kidney disease.
The research team led by the University of Edinburgh analyzed the data set as part of the EAVE II project, which uses anonymously linked patient data to track pandemics and vaccine promotion in real time.
They surveyed data on people in Scotland who had received the first dose of the two vaccines as of April 14, 2021. By this day, more than 1.7 million people had been vaccinated by Oxford-AstraZeneca, and about 800,000 people had been vaccinated by Pfizer-BioNTech.
Researchers–with the University of Strathclyde, University of Aberdeen, University of Glasgow, University of Oxford, University of Swansea and University of St Andrews, Victoria University of Wellington, Queen’s University of Belfast and The Public Health Service of Scotland (PHS) collaborated-also reviewed health records dating back to September 2019 to investigate any previous issues related to ITP, blood clotting or bleeding disorders.
The researchers then compare these data–including GP records, hospital admissions records, death registrations, and laboratory test results about vaccinations–with people who have not been vaccinated to determine whether there are Any coagulation event exceeds expectations before the pandemic.
Data show that people vaccinated with Oxford-AstraZeneca vaccine have a slight increase in ITP in the second week after vaccination, and may also increase the risk of arterial clotting and bleeding events.
There may be 11 cases of ITP per million people vaccinated, which is similar to the number of hepatitis B vaccine, measles vaccine and flu vaccine, which have 10 to 30 cases per million people vaccinated Example ITP.
The research team found no adverse events related to ITP, coagulation or bleeding when analyzing Pfizer-BioNTech’s vaccine. Experts say that although this study adds to the evidence that Oxford-AstraZeneca vaccination is associated with blood clots and ITP, it has not yet clearly demonstrated a causal relationship. This is under active investigation.
Researchers say that the two-week lag of hospital data may mean that some data are missing, which may limit the results of the study. The study also included a relatively small number of young vaccinators under the age of 40, especially the Oxford-AstraZeneca vaccine, because Scotland’s vaccination plan follows the recommendations of the Joint Committee on Vaccination and Immunization, which prioritizes the elderly and vulnerable Adults get vaccinated.
These results were published in the journal “Natural Medicine”. The research was funded by the Medical Research Council, the UK Research and Innovation Industry Strategic Challenge Fund and the UK Health Data Research (HDR UK), and was supported by the Scottish government.
Additional support is provided through the Director-General of Health and Social Care of the Scottish Government, and the UKRI COVID-19 National Core Research Data and Connection Program led by the UK HDR Company.
If the public has side effects after vaccinating the Oxford-AstraZeneca vaccine, or if they want more information, the researchers recommend that they seek the information in the AstraZeneca COVID-19 vaccine and rare blood clot brochure , The brochure is available on the NHS Inform website.
Professor Aziz Sheikh, Director of the Usher Institute at the University of Edinburgh and head of EAVE II research, said: “This careful analysis of the entire country’s vaccination plan involves research on more than 2.5 million first doses of vaccines. It was found that the risk of ITP, coagulation and bleeding events after the Oxford-AstraZeneca vaccine slightly increased. This very small risk is important, but it requires very obvious benefits in the vaccine and these results in people who have developed COVID-19 Of the potential high-risk context.”
The lead author of the study, Professor Colin Simpson of Victoria University of Wellington, said. “It is gratifying that we did not find that people receiving Pfizer-BioNTech’s mRNA vaccine have an increased overall risk of ITP, coagulation, and bleeding events. We are now planning to update our analysis because the vaccine program is being expanded to younger and younger. Healthy people, and new vaccines are emerging.””
Professor Chris Robertson from the University of Strathclyde and Scottish Public Health said: “This study shows the ability to link large national data sets Together, the advantages of using some analysis methods to provide near real-time vaccine safety information. The next important step is to replicate this work in other environments to ensure that the research results are robust. ”
Professor Andrew Morris, Director of Health Data Research UK (HDR UK) and Vice Chancellor of Data Science at the University of Edinburgh, said: “This is a good example of why access to health data is essential for important research Important, it can quickly provide information for responding to the COVID 19 pandemic. This research is important to individuals, the NHS, policy makers, and the world. In order to carry out this work safely, the UK has established the ability to conduct secure and confidential data analysis so that important research questions can be answered in a trustworthy way. UK HDR and the National Bureau of Statistics National Core Research support the UK Health Innovation Gateway, providing researchers with a common portal to discover and request access to UK health data sets for important research that improves people’s lives. “